When should I pick LGD-2226 over LGD-4033?

Pick LGD-2226 if: - Targeting bone strength/density as a primary endpoint - Prioritizing low androgenic and estrogenic activity (e.g., sensitive to prostate or scalp issues) - Interested in experimental SARMs or completing a SARM portfolio - Chasing libido preservation (per rodent models) - Stacking with MK-677 or GH-axis peptides for joint or bone benefits Pick LGD-4033 if: - Lean mass and strength increase are main goals - Want a SARM with a robust, well-documented cycle structure and side effect profile - Interested in proven 8-week bulking or recomp runs - Prioritize reliable sourcing and compound purity - Looking for support and shared experience in the community for troubleshooting protocols

Comparison

LGD-2226 vs LGD-4033

Q: LGD-2226 vs LGD-4033: which is better?

LGD-2226 wins for low androgenic sides, minimal prostate impact, and theoretical long-term bone gains without libido suppression (per rodent data). LGD-4033 wins for clinical-grade lean mass accrual, larger human dataset, easy sourcing, and predictable results in strength, recomp, or cutting protocols. If raw anabolism, reliability, or community integration is the metric, LGD-4033 is the clear leader.

Old-school quinolinone SARM for bone vs. flagship lean-mass gainer.

LGD-2226

Nonsteroidal Selective Androgen Receptor Modulator

SARMt½ Not formally published; once-daily oral dosing supported in preclinical models

LGD-4033

Selective Androgen Receptor Modulator

SARMt½ 24–36 hours

Effectiveness Profile

LGD-2226

LGD-4033

At a Glance

	LGD-2226	LGD-4033
Type	SARM	SARM
Legal status	Research	Research
Half-life	Not formally published; once-daily oral dosing supported in preclinical models	24–36 hours
Preferred route	Oral	Oral
Dose frequency	once-daily	once-daily
Beginner dose	2.5–5 mg	5–5 mg
Intermediate dose	5–10 mg	5–10 mg
Advanced dose	10–15 mg	10–20 mg
Cycle length	6–12 wks	6–8 wks
Bioavailability	—	90%
Time to peak	2h	2h
Active duration	24h	24h
Storage	Room temperature, sealed, protected from light and moisture	Room temperature, dry, away from light
PCT required	Yes	Yes
Ancillaries required	Yes	Yes
Safe for women	No	No
Anabolic / androgenic	200 / 50	500 / 1

Verdict

LGD-2226 wins for low androgenic sides, minimal prostate impact, and theoretical long-term bone gains without libido suppression (per rodent data).

LGD-4033 wins for clinical-grade lean mass accrual, larger human dataset, easy sourcing, and predictable results in strength, recomp, or cutting protocols. If raw anabolism, reliability, or community integration is the metric, LGD-4033 is the clear leader.

Pick A or B?

Pick LGD-2226 if:

Targeting bone strength/density as a primary endpoint
Prioritizing low androgenic and estrogenic activity (e.g., sensitive to prostate or scalp issues)
Interested in experimental SARMs or completing a SARM portfolio
Chasing libido preservation (per rodent models)
Stacking with MK-677 or GH-axis peptides for joint or bone benefits

Pick LGD-4033 if:

Lean mass and strength increase are main goals
Want a SARM with a robust, well-documented cycle structure and side effect profile
Interested in proven 8-week bulking or recomp runs
Prioritize reliable sourcing and compound purity
Looking for support and shared experience in the community for troubleshooting protocols

See more on Looksmaxxing

This comparison is presented for informational and educational purposes only. The compounds described may be research chemicals, prescription-only, or regulated substances in your jurisdiction. Consult a qualified medical professional before using any compound. This is not medical advice.